Understanding the Tip:
Why container–product interaction studies are critical:
Pharmaceutical formulations are often stored in containers made of plastic, glass, or other elastomeric materials. These materials are not inert—interaction with the drug product can occur over time through adsorption (loss of drug or excipients to the surface) or leaching (migration of substances from the container into the formulation). These phenomena can alter the stability, safety, and efficacy of the product, making it essential to evaluate them throughout the shelf life.
Consequences of undetected container wall interactions:
Failure to study adsorption and leaching may result in:
- Reduced API concentration or potency at later time points
- Appearance of extractable or leachable impurities
- Subvisible particulate formation or pH drift
- Regulatory queries during product approval or audits
This is particularly critical for biologics, injectable drugs, and oral liquids packaged in plastics or low-volume delivery systems.
Regulatory and Technical Context:
ICH and WHO requirements for container compatibility:
ICH Q1A(R2) mandates testing of the dosage form in its final container closure system under defined storage conditions. WHO TRS 1010 emphasizes evaluation of packaging system impact on product quality. ICH Q3D and USP / also provide guidance on extractables and leachables. Data generated from these studies must be documented in CTD Module 3.2.P.2 (Pharmaceutical Development) and P.8.3 (Stability Summary).
Audit
Inspectors frequently look for evidence that container materials do not compromise product quality over time. Missing data on adsorption or leaching can lead to questions about shelf-life validity or packaging adequacy. Including this testing demonstrates robust risk management and quality-by-design alignment.
Best Practices and Implementation:
Design interaction studies specific to container type and product:
Evaluate based on packaging material:
- Glass: Check for ion leaching (e.g., sodium, boron) and pH changes
- Plastic: Assess loss of API or preservatives due to adsorption
- Rubber stoppers: Screen for extractable additives or colorants
Use matched placebos and API solutions for accurate interpretation of surface effects versus chemical degradation.
Monitor interaction effects across stability time points:
Include container-interaction parameters in your stability protocol:
- Assay variation due to adsorption (compare to glass reference)
- Appearance of leachables via LC-MS or ICP-MS
- Particulate evaluation and visual inspection
- pH drift and microbial contamination risks
Document all changes and assess clinical impact if leachables exceed permitted daily exposure (PDE) limits.
Support regulatory claims with container compatibility data:
Include:
- Justification for material selection based on compatibility testing
- Stability data showing no adverse interactions
- Extractables/leachables profiles under worst-case conditions
Summarize results in your dossier and include supportive SOPs, method validations, and certificates of compliance from packaging suppliers.
Performing container wall interaction studies helps ensure product quality, reduce regulatory risk, and protect patients—especially in complex formulations or sensitive dosage forms. This is an essential part of modern stability and packaging science.